- Home
- ETON vs CELC Comparison
ETON vs CELC Comparison
Compare ETON & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- CELC
- Stock Information
- Founded
- ETON 2017
- CELC 2011
- Country
- ETON United States
- CELC United States
- Employees
- ETON N/A
- CELC N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- CELC Medical Specialities
- Sector
- ETON Health Care
- CELC Health Care
- Exchange
- ETON Nasdaq
- CELC Nasdaq
- Market Cap
- ETON 388.3M
- CELC 440.0M
- IPO Year
- ETON 2018
- CELC 2017
- Fundamental
- Price
- ETON $14.39
- CELC $42.16
- Analyst Decision
- ETON Strong Buy
- CELC Strong Buy
- Analyst Count
- ETON 3
- CELC 6
- Target Price
- ETON $29.67
- CELC $39.67
- AVG Volume (30 Days)
- ETON 420.1K
- CELC 2.4M
- Earning Date
- ETON 08-07-2025
- CELC 08-13-2025
- Dividend Yield
- ETON N/A
- CELC N/A
- EPS Growth
- ETON N/A
- CELC N/A
- EPS
- ETON N/A
- CELC N/A
- Revenue
- ETON $48,327,000.00
- CELC N/A
- Revenue This Year
- ETON $101.12
- CELC N/A
- Revenue Next Year
- ETON $45.71
- CELC N/A
- P/E Ratio
- ETON N/A
- CELC N/A
- Revenue Growth
- ETON 40.88
- CELC N/A
- 52 Week Low
- ETON $3.25
- CELC $7.58
- 52 Week High
- ETON $21.48
- CELC $46.42
- Technical
- Relative Strength Index (RSI)
- ETON 45.76
- CELC 90.56
- Support Level
- ETON $13.78
- CELC $38.00
- Resistance Level
- ETON $15.73
- CELC $46.42
- Average True Range (ATR)
- ETON 0.75
- CELC 2.45
- MACD
- ETON -0.01
- CELC 2.71
- Stochastic Oscillator
- ETON 31.98
- CELC 79.33
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.